Q1 2024 Outset Medical Inc Earnings Call Transcript
Key Points
- FDA clearance for Tablo cart with pre-filtration achieved ahead of schedule, enhancing Outset Medical Inc's product ecosystem and expected to positively impact the remainder of the year.
- Implemented a significant restructuring plan expected to reduce cash use through 2027 by over $100 million, aligning with the company's goal to reach cash flow breakeven sooner without additional capital.
- Reported a strong recurring revenue model, which now represents more than 50% of total revenue, providing a stable and predictable income stream.
- Achieved 12 consecutive quarters of gross margin expansion, reaching 31.1% non-GAAP gross margin, demonstrating effective cost management and operational efficiency.
- Expanded the acute care pipeline significantly, with over 60% of deals valued over $1 million each, and more than half representing new potential customers, indicating robust growth potential.
- Reported lower than anticipated revenue of $28.2 million for the quarter, primarily due to ongoing headwinds including a regulatory hold on Tablo cart and disruptions from the Change Healthcare cyber attack.
- Experienced several customer deferrals in both treatment and console purchases due to the Change Healthcare attack, impacting financial performance.
- Acknowledged the need to reestablish sales, marketing, and contracting activities following the pause due to the Tablo cart ship hold, which may affect short-term revenue growth.
- Reported a decline in product revenue to $20.4 million in Q1, a decrease from the previous quarter, reflecting ongoing challenges in the market.
- Anticipated a need for customers to rebudget funds for purchases due to previous deferrals, which could delay revenue recognition in the short term.
Good day, and thank you for standing by, and welcome to the Outset Medical Q1 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded, and I would like to turn the conference over to your speaker today, Jim Mazzola, Head of Investor Relations. Please go ahead.
Okay. Thank you, and good afternoon, everyone. Welcome to our first quarter 2024 earnings call here with me today are Leslie Trigg, Chair and Chief Executive Officer, and the BLM ED, Chief Financial Officer. We issued a news release after the close of market today, which can be found on the investor pages of outset, medical.com. This call is being recorded and will be archived on the investor section of our website. It is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995.
These statements relate to expectations or predictions of future events are based on our current estimates and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
